Key result
Oral quinidine bioavailability was similar in patients with congestive heart failure (72%) compared to control cardiac patients (73%), although the rate of absorption was slower.
Why the study?
Does congestive heart failure alter the oral bioavailability of quinidine compared to non-heart failure cardiac patients?
Population
8 patients with moderate to severe congestive heart failure and an unspecified number of control cardiac…
Comparison
Quinidine gluconate 400 mg administered by… vs Control cardiac patients (non-heart failure).
Design
Cohort
Follow-up
48 hours
Authors
Loading...
Slower absorption in heart failure may delay onset; leaves open whether rate-adjusted regimens warrant prospective testing.
Does congestive heart failure alter the oral bioavailability of quinidine compared to non-heart failure cardiac patients?
Absolute Event Rate: 72% vs 73%
Patients with congestive heart failure have a slower rate of quinidine absorption but similar overall bioavailability compared to non-heart failure patients, suggesting they may require smaller oral dosages to achieve therapeutic concentrations.
Ueda et al. (1981) studied congestive heart failure (n=8). quinidine gluconate vs. control cardiac patients was evaluated on extent of quinidine absorption. Oral quinidine bioavailability was similar in patients with congestive heart failure (72%) compared to control cardiac patients (73%), although the rate of absorption was slower.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: